Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic Value of Circulating Tumor Cells and Cancer Associated Macrophage-Like Cells in Metastatic Non-Small Cell Lung Cancer Patients: A Retrospective Exploratory Analysis.

Oncology research·2026
Same author

Corrigendum to "International expert consensus on the clinical integration of circulating tumor cells in solid tumors" [Eur. J. Cancer 231 (2025) 116050].

European journal of cancer (Oxford, England : 1990)·2025
Same author

International expert consensus on the clinical integration of circulating tumor cells in solid tumors.

European journal of cancer (Oxford, England : 1990)·2025
Same author

The ACCEPTance of automation: refining circulating tumor cells enumeration for improved metastatic colorectal cancer prognosis.

Molecular oncology·2025
Same author

Evolution of Neo-RAS-WT in Circulating Tumor DNA from First-Line to Subsequent Therapies in Metastatic Colorectal Cancer.

Cancers·2025
Same author

Exploring the utility of a NGS multigene panel to predict BCG response in patients with non-muscle invasive bladder cancer.

Oncology research·2025

Related Experiment Video

Updated: May 10, 2026

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications
14:14

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

Controversies in circulating tumor cell count during therapy.

Cristina Raimondi1, Angela Gradilone, Paola Gazzaniga

  • 1Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 324, 00161 Rome, Italy.

Expert Review of Molecular Diagnostics
|June 21, 2013
PubMed
Summary

Circulating tumor cells (CTCs) show promise as biomarkers for cancer prognosis and treatment response. However, definitive validation is needed to integrate CTC analysis into routine clinical practice due to cellular heterogeneity.

More Related Videos

Circulating Tumor Cell Lines: an Innovative Tool for Fundamental and Translational Research
07:47

Circulating Tumor Cell Lines: an Innovative Tool for Fundamental and Translational Research

Published on: December 25, 2021

Microfluidics-based High-throughput Circulating Tumor Cell Sorting and Single-cell Sequencing Technology
09:45

Microfluidics-based High-throughput Circulating Tumor Cell Sorting and Single-cell Sequencing Technology

Published on: November 14, 2025

Related Experiment Videos

Last Updated: May 10, 2026

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications
14:14

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

Circulating Tumor Cell Lines: an Innovative Tool for Fundamental and Translational Research
07:47

Circulating Tumor Cell Lines: an Innovative Tool for Fundamental and Translational Research

Published on: December 25, 2021

Microfluidics-based High-throughput Circulating Tumor Cell Sorting and Single-cell Sequencing Technology
09:45

Microfluidics-based High-throughput Circulating Tumor Cell Sorting and Single-cell Sequencing Technology

Published on: November 14, 2025

Area of Science:

  • Oncology
  • Molecular Biology
  • Biomarker Discovery

Background:

  • Circulating tumor cells (CTCs) are investigated as biomarkers for cancer prognosis and predicting therapeutic response.
  • Molecular profiling of CTCs offers potential insights into cancer biology and personalized treatment strategies.
  • Current clinical data on the utility of CTC molecular information for patient benefit remain inconclusive.

Purpose of the Study:

  • To highlight the potential of circulating tumor cells (CTCs) as biomarkers.
  • To discuss the challenges in translating CTC analysis to clinical practice.
  • To emphasize the need for definitive validation of CTCs in routine oncological care.

Main Methods:

  • Review of current literature on circulating tumor cells (CTCs).
  • Analysis of the potential and limitations of CTC enumeration and molecular characterization.
  • Discussion of the challenges in clinical validation of CTCs.

Main Results:

  • CTCs hold promise as prognostic and predictive biomarkers.
  • Molecular characterization of CTCs can provide insights into cancer biology.
  • Clinical utility of CTC molecular data requires further validation.

Conclusions:

  • Definitive validation is required to incorporate CTC count and characterization into routine oncological practice.
  • The extreme heterogeneity of CTCs presents a significant challenge for molecular profiling.
  • Further research is essential to overcome limitations and establish CTCs as reliable clinical tools.